Girardi DM, Niglio SA, Mortazavi A, Nadal R, et al. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res 2022;28:1353-1362.
PMID: 35031545